2HZ4 image
Entry Detail
PDB ID:
2HZ4
Keywords:
Title:
Abl kinase domain unligated and in complex with tetrahydrostaurosporine
Biological Source:
Source Organism:
Host Organism:
PDB Version:
Deposition Date:
2006-08-08
Release Date:
2007-01-16
Method Details:
Experimental Method:
Resolution:
2.80 Å
R-Value Free:
0.28
R-Value Work:
0.21
Space Group:
C 1 2 1
Macromolecular Entities
Polymer Type:polypeptide(L)
Description:Proto-oncogene tyrosine-protein kinase ABL1
Chain IDs:A, B, C
Chain Length:273
Number of Molecules:3
Biological Source:Homo sapiens
Ligand Molecules
Primary Citation
Structural biology contributions to the discovery of drugs to treat chronic myelogenous leukaemia.
ACTA CRYSTALLOGR.,SECT.D 63 80 93 (2007)
PMID: 17164530 DOI: 10.1107/S0907444906047287

Abstact

Chronic myelogenous leukaemia (CML) results from the Bcr-Abl oncoprotein, which has a constitutively activated Abl tyrosine kinase domain. Although most chronic phase CML patients treated with imatinib as first-line therapy maintain excellent durable responses, patients who have progressed to advanced-stage CML frequently fail to respond or lose their response to therapy owing to the emergence of drug-resistant mutants of the protein. More than 40 such point mutations have been observed in imatinib-resistant patients. The crystal structures of wild-type and mutant Abl kinase in complex with imatinib and other small-molecule Abl inhibitors were determined, with the aim of understanding the molecular basis of resistance and to aid in the design and optimization of inhibitors active against the resistance mutants. These results are presented in a way which illustrates the approaches used to generate multiple structures, the type of information that can be gained and the way that this information is used to support drug discovery.

Legend

Protein

Chemical

Disease

Primary Citation of related structures